35 GATEHOUSE DRIVE, WALTHAM, MA
FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
Changes in Board, Management or Compensation
Changes in Board, Management or Compensation, Reg. FD
Reports First Quarter 2025 Financial Results and Provides Business Update
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FDA Approves Revuforj® for Acute Leukemia with KMT2A Translocation
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities